REMARKS

In response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, applicants subjoin a sequence listing to the instant application. A computer readable sequence listing on 3.5 inch floppy diskette is enclosed as well. The sequence listing information recorded in computer readable form is identical to the written sequence listing. 37 CFR § 1.821(f).

The indicated portions of the specification have been supplemented with sequence identification numbers SEQ ID NO.1 – SEQ ID NO. 35 interposed after nucleotide sequences. 37 CFR § 1.821 (d). No new matter has been introduced. 37 CFR § 1.821(g).

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Philip B. Polster II
Reg. No. 43,864
(314) 694-9094
(314) 694-9095 (facsimile)

Pharmacia Corporation
Corporate Patent Department O4E
800 North Lindbergh Boulevard
St. Louis, Missouri 63167

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Richardo Rocha et al.
Serial No. 09/916,136
Filed July 26, 2001
For: ALDOSTERONE BLOCKER THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED DISORDERS
Art Unit 1614

July 1, 2002

AMENDMENT A – Version with Markings to show Changes Made

IN THE SPECIFICATION

Page 110, first paragraph, lines 1-5, please deleted the indicated section and replace with:

In situ Hybridization for Osteopontin mRNA

RNA probes were generated based on a sequence for rat osteopontin (GenBank accession# NM 008608-1). Briefly, a cDNA fragment of rat osteopontin was generated by RT-PCR using the following primers: forward primer, 5'-TGG CAC ATT TGT CTT (SEQ ID NO. 1); reverse primer 3'AGC CCA TCC AGTC (SEQ ID NO. 2).

Page 111-112, Table 8 (Page 111, line 24-Page 112, lines 1-5), please delete Table 8 and replace with:

Table 8 TaqMan RT-PCR Gene Marker Primer/Probe Sets

Gene	Forward Primer	Reverse Primer	Probe
Transforming growth factor beta 1(TGFβ1)	CACCATCCATGA CATGAACC (SEQ. ID NO. 3)	ACCTTGCTGTACTG TGTGTCC (SEQ. ID NO.4)	TCAGCTCCACAG AGAAGAACTGC (SEQ. ID NO. 5)
Atrial natriuretic factor (ANP)	TGGGCTCCTTCTC CATCAC (SEQ. ID NO. 6)	AGCAGAGCCCTCA GTTTG (SEQ. ID NO. 7)	CCATATTGGAGC AAATCCCGTATA C (SEQ. ID NO. 8)
Collagen I	ACCAAGGCTGCA ACCTGGA (SEQ. ID NO. 9)	GCAGGAAGGTCAG CTGGAT (SEQ. ID NO. 10)	CCATACTCGAAC TGGAATCCATCG (SEQ. ID NO. 11)
Collagen III	GGCTTTCAGTTC AGCTATGG	GACTGTCTTGCTCC ATTCAC	CCTGATCTTCCTG AAGATGTCCTTG

	(SEQ. ID NO. 12)	(SEQ. ID NO. 13)	(SEQ. ID NO. 14)
Cyclophilin	CTTGTCCATGGC AAATGCTG (SEQ. ID NO. 15)	GTGATCTTCTTGCT GGTCTTGC (SEQ. ID NO. 16)	CCACAATGCTCA TGCCTTCTTTCAC C (SEQ. ID NO. 17)
Cyclooxegen ase-2 (COX-2)	TCAAAGACACTC AGGTAGA CATGATCT (SEQ. ID NO. 18)	CGGCACCAGACCA AAGACTT (SEQ. ID NO. 19)	CACGTCCCTGAG CACCTGCGG (SEQ. ID NO. 20)
Osteopontin	CCAGCACACAAG CAGACGTT (SEQ. ID NO. 21)	TCAGTCCATAAGCC AAGCTATCAC (SEQ. ID NO. 22)	CAGTCGATGTCC CTGACGGCCG (SEQ. ID NO. 23)
Monocyte Chemoattract ant Protein-1 (MCP-1)	GCAGGTCTCTGT CACGCTTCT (SEQ. ID NO. 24)	GGCTGAGACAGCA CGTGGAT (SEQ. ID NO. 25)	CCTGTTGTTCAC AGTTGCTGCCTG TAGC (SEQ. ID NO. 26)
Intercellular Adhesion Molecule-1 (ICAM-1)	ACCTGCAGCCGG AAAGC (SEQ. ID NO. 27)	CCCGTTTGACAGAC TTCACCAT (SEQ. ID NO. 28)	CCGATAGGCAGC GGGACACCA (SEQ. ID NO. 29)
Vascular Cell Adhesion Molecule - 1(VCAM-1)	GAAGCCGGTCAT GGTCAAGT (SEQ. ID NO. 30)	GGTCACCCTTGAAC AGTTCTATCTC (SEQ. ID NO. 31)	TGGCTCCTGATG TTTACCCAATTG ACAGA (SEQ. ID NO. 32)
Cyclophilin	AGAGAAATTTGA GGATGAGAACTT CAT (SEQ. ID NO. 33)	TTGTGTTTGGTCCA GCATTTG (SEQ. ID NO. 34)	AAGCATACAGGT CCTGGCATCTTG TCCAT (SEQ. ID NO. 35)